// App-Quantinova.ai

2157 : Enhanced in vitro activity of dianhydrogalactitol (VAL-083) in combination with platinum drugs: Impact of p53 and platinum-resistance

Researchers

Presenter

  • Anne Steino

Principal Investigators

  • Guanghan He

  • Michelle Martinez-Rivera

  • Jeffrey A. Bacha

  • Dennis M. Brown

  • Zahid H. Siddik

Medical Centers

  • Jazz Pharmaceuticals, Vancouver, British Columbia, Canada.

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • DelMar Pharmaceuticals, San Francisco, CA.

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

  • Ovarian cancer

  • Lung Cancer

  • Solid malignancies

  • Gliomas

Biomarkers

  • p53

Drug/Treatment

  • Dianhydrogalactitol

  • Oxaliplatin

  • Cisplatin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved